GSK gains 2% after winning another Zantac case and placing of £840 million Haleon shares
Canadian court dismisses proposed class actionLack of scientific evidence Zantac causes cancerSuccessful placing of £840 million Haleon sharesShares in global biopharma giant GSK (GSK) jumped 1.7% to £14.68 on Friday following news...
12 May 2023